Journal article
Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
Abstract
BackgroundReal-world data on transitioning to Immune Globulin Subcutaneous (Human) 20% solution (Ig20Gly) are limited. This study aimed to assess infusion parameters and experience of patients with primary (PID) or secondary immunodeficiencies (SID) transitioning to Ig20Gly in clinical practice in Canada.MethodsPatients with PID or SID who received subcutaneous immunoglobulin (SCIG) for ≥ 3 months before transitioning to Ig20Gly were eligible …
Authors
Keith PK; Cowan J; Kanani A; Kim H; Lacuesta G; Lee JK; Chen J; Park M; Gladiator A
Journal
Allergy, Asthma & Clinical Immunology, Vol. 18, No. 1,
Publisher
Springer Nature
DOI
10.1186/s13223-022-00709-8
ISSN
1710-1484